# A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Source: https://onco.cc/trials/nct05150691/  
OnCo record `nct05150691` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Trastuzumab pamirtecan and Pertuzumab in advanced solid tumours, run by DualityBio Inc., now recruiting.

## Summary

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05150691 by DualityBio Inc., with 796 participants planned, started 2022-01-31 and due to reach its primary completion in 2027-08. Interventions recorded: DB-1303/BNT323, Pertuzumab Injection, Ritonavir and Itraconazole.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05150691
- Phase: 1/2
- Setting: A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors
- Sponsor: DualityBio Inc.
- Enrolled: 796

## Sources

- ClinicalTrials.gov NCT05150691: https://clinicaltrials.gov/study/NCT05150691

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Pertuzumab](https://onco.cc/drugs/pertuzumab/), [Trastuzumab pamirtecan](https://onco.cc/drugs/trastuzumab-pamirtecan/)
- companies: [BioNTech](https://onco.cc/companies/biontech/), [Duality Biotherapeutics](https://onco.cc/companies/dualitybio/)

---
JSON: https://onco.cc/api/v1/entities/nct05150691.json